Orphalan to Showcase Scientific Research and Educational Programming at The Liver Meeting® 2026

Company-sponsored research includes five poster presentations, one of which was awarded a poster of distinction, and an oral presentation highlighting advances in Wilson disease monitoring, treatment experience, and clinical trial innovation

CHICAGO, Nov. 2, 2026 /PRNewswire/ -- Orphalan Inc., the US affiliate of a global pharmaceutical company dedicated to improving the lives of people living with rare diseases, today announced its participation in The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5-9, 2026, in Denver, Colorado.

At this year's meeting, Orphalan-sponsored research will be featured in five poster presentations and one oral presentation focused on Wilson disease. Research topics include approaches to disease monitoring, treatment adherence, patient experience, and an investigational once-daily trientine tetrahydrochloride formulation.

"We are pleased to share new scientific findings that reflect our ongoing commitment to advancing the understanding and management of Wilson disease," said Jamie Heise, Senior Director, U.S. Medical Affairs, Orphalan. "Through collaboration with researchers and healthcare professionals, we continue to generate meaningful evidence to better understand disease monitoring, inform clinical practice, and address unmet needs in the Wilson disease community."

Scientific Presentations

Poster Presentations

Thursday, November 5, 2026 | 12:00 PM-1:00 PM

• Poster 1419: Poster of Distinction, Can a Novel Instant Release Trientine Tetrahydrochloride Formulation Be Effective When Administered Once-Daily? Results of the TRIUMPH-3 Pharmacokinetic Study,
  Presenter: Michael Schilsky, MD, FAASLD
• Poster 1425: Real World Evidence of Therapy Impact of Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool in Newly Diagnosed Wilson Disease
  Presenter: Michael Schilsky, MD, FAASLD
• Poster 1428: Virtual CME Simulation Improves Multi-Specialty Performance in the Diagnosis and Management of Wilson Disease
  Presenter: Jovana Lubarda, PhD
• Poster 1430: Understanding the Drivers of Treatment Experience and Adherence in Wilson Disease-- What Do Patient Interviews and Reported Outcomes from a Phase 2 Study Evaluating a New Trientine Tetrahydrochloride Formulation Tell Us?
  Presenter: Emmanuel Tsochatzis MD, PhD, MSc, FEBTM, FRCP
• Poster 1434: De-centralized Clinical Trials in Rare Disease; Incorporating the Patient Voice in the Evaluation of Tolerability, Treatment Satisfaction and Adherence of a Novel Trientine Tetrahydrochloride Formulation for the Treatment of Wilson Disease
  Presenter: Emmanuel Tsochatzis MD, PhD, MSc, FEBTM, FRCP

Oral Presentation

Sunday, November 8, 2026 | 11:45 AM-12:00 PM

• Real World Evidence of Therapy Impact in Unstable Wilson Disease Using Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool - Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries
  Presenter: Michael Schilsky, MD, FAASLD

Industry Theater Presentation

In addition to the scientific presentations, Orphalan will host an industry theater session.

Peer to Peer Series on Wilson Disease: Unmet Needs in Wilson Disease, Strategies for Long-Term Management, and the Role of an Approved Treatment Option

Date: November 8, 2026
Time: 1:30 PM-2:00 PM
Location: TLM Theater #2, Exhibit Hall F, Colorado Convention Center
Speaker: Robert G. Gish, MD, FAASLD

This promotional presentation will explore ongoing unmet needs in Wilson disease, discuss strategies for long-term disease management, and review the role of an approved treatment option.

Visit Orphalan at Booth #1173

Conference attendees are invited to visit Booth #1173 to learn more about Orphalan's commitment to the Wilson disease community and its ongoing efforts to advance research, education, and patient-focused care.

About Wilson Disease

Wilson disease is a rare inherited disorder of copper metabolism caused by mutations in the ATP7B gene. The disease prevents the body from eliminating excess copper, leading to toxic accumulation in tissues and organs, primarily the liver and brain. Without lifelong treatment, Wilson disease can give rise to serious hepatic, neurologic, and psychiatric complications, and importantly, untreated Wilson disease can be fatal. 

About Orphalan

Orphalan is a pharmaceutical company dedicated to developing and commercializing treatments for rare diseases, including Wilson disease. The company's portfolio has recently expanded to include infantile epileptic spasms syndrome (IESS), a rare form of pediatric epilepsy, as well as neuro-oncology, focusing on conditions with significant unmet medical need. By combining scientific rigor with a strong patient-centered mindset, Orphalan works closely with healthcare professionals and patient communities to improve standards of care. Its model emphasizes deep medical engagement, long-term partnerships, and sustainable access to therapies, ensuring that people living with rare and often overlooked disorders receive tailored, specialized treatment options. Find out more at www.orphalan.com

US-ORPH-CORP-26048

SOURCE Orphalan